This site is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Nutrition 21 Awarded Grant for Diabetic Technology

PURCHASE, N.Y.—Nutrition 21 Inc., the developer and marketer of clinically substantiated ingredients for dietary supplements, foods and beverages, and animal nutrition, announced the award of a cash grant of up to $104,350 from the Federal Qualifying Therapeutic Discovery Project (QTDP) Program to help further develop its patent pending chromium-enhanced insulin technology for use in the treatment of type 1 and type 2 diabetes.

James Komorowski, vice president, research & development, stated: "We are very excited to receive the financial support to advance the development of our technology surrounding a novel chromium-enhanced insulin drug that may reduce the risk and symptoms of hypoglycemia (very low blood sugar caused by excessive insulin doses), reduce weight gain caused by insulin use and be more effective than insulin drugs currently on the market. We are grateful the QTDP Program recognized the potential of this novel technology and awarded us this grant."

Michael Zeher, Nutrition 21's president and chief executive officer, stated: "This grant demonstrates recognition of the cutting edge technology the company is developing. Since the QTDP process is rigorous, we're particularly gratified that we were approved. It's a noteworthy indicator of the innovative science and valuable potentials inherent at Nutrition 21."

comments powered by Disqus